Matsumura’s group reported that anti-TF-ADC, compared with control ADC treatment, significantly enhanced drug accumulation and penetration of tumors in a stromal-rich orthotopic pancreatic cancer model [74,75]. The gene discussed is TF; the disease is pancreatic neoplasm.